Rigel Pharmaceuticals Inc. (New)
RIGL Real Time Price USDRecent trades of RIGL by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by RIGL's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$10,000 Jul 16, 2021 Issue: Health Issues
-
$20,000 Jul 16, 2021 Issue: Health Issues
Estimated quarterly lobbying spending
RIGL Revenue by Segment or Geography
New patents grants
-
Patent Title: Method for treatment of covid-19-associated conditions Apr. 01, 2025
-
Patent Title: Tgf-β inhibitors Feb. 18, 2025
-
Patent Title: Heterocyclic rip1 kinase inhibitors Dec. 03, 2024
-
Patent Title: Rip1 inhibitory compounds and methods for making and using the same Oct. 15, 2024
-
Patent Title: Rip1k inhibitors Jul. 23, 2024
-
Patent Title: Benzazole compounds and methods for making and using the compounds Jul. 23, 2024
-
Patent Title: Irak inhibitors and method for making and using May. 28, 2024
-
Patent Title: Ret inhibitor for use in treating cancer having a ret alteration Apr. 23, 2024
-
Patent Title: Amide compounds and method for making and using Mar. 26, 2024
-
Patent Title: Compositions and methods for inhibition of the jak pathway Nov. 28, 2023
-
Patent Title: Tyrosine kinase inhibitors Jun. 13, 2023
-
Patent Title: Rip1k inhibitors Jun. 06, 2023
-
Patent Title: Compositions and methods for inhibition of the jak pathway Jun. 06, 2023
-
Patent Title: Rip1k inhibitors Feb. 21, 2023
-
Patent Title: Heterocyclic rip1 inhibitory compounds Feb. 14, 2023
-
Patent Title: Rip1 inhibitory compounds and methods for making and using the same Jan. 31, 2023
-
Patent Title: Amide compounds and method for making and using Dec. 20, 2022
-
Patent Title: 2,4-diamino-pyrimidine compounds and method for making and using the compounds Dec. 13, 2022
-
Patent Title: Irak inhibitors and method for making and using Nov. 08, 2022
-
Patent Title: Heterocyclic rip1 kinase inhibitors Oct. 25, 2022
-
Patent Title: Rip1 inhibitory compounds and methods for making and using the same Oct. 18, 2022
-
Patent Title: Tgf-β inhibitors Oct. 11, 2022
-
Patent Title: Rip1 inhibitory compounds and methods for making and using the same Aug. 09, 2022
-
Patent Title: Rip1 inhibitory compounds and methods for making and using the same Jul. 05, 2022
-
Patent Title: Pyrazole compounds and methods for making and using the compounds Jun. 28, 2022
-
Patent Title: Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations Jun. 28, 2022
-
Patent Title: Rip1 inhibitory compounds and methods for making and using the same Jun. 28, 2022
-
Patent Title: Rip1 inhibitory compounds and methods for making and using the same Jun. 28, 2022
-
Patent Title: Rip1 inhibitory compounds and methods for making and using the same May. 17, 2022
-
Patent Title: Benzazole compounds and methods for making and using the compounds Apr. 12, 2022
-
Patent Title: Nrf2 activating compounds and uses thereof Mar. 22, 2022
-
Patent Title: Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds Jan. 25, 2022
-
Patent Title: Prodrugs of 2,4-pyrimidinediamine compounds and their uses Jan. 25, 2022
-
Patent Title: Compounds and method for treating autoimmune diseases Jan. 11, 2022
-
Patent Title: Compositions and methods for inhibition of the jak pathway Dec. 14, 2021
-
Patent Title: Compositions and methods for inhibition of the jak pathway Nov. 16, 2021
-
Patent Title: Direct ampk activators Nov. 16, 2021
-
Patent Title: Fumarate analogs and uses thereof Sep. 28, 2021
-
Patent Title: Tyrosine kinase inhibitors Sep. 07, 2021
-
Patent Title: Acvr2a-specific antibody and method of treatment of muscle atrophy Aug. 31, 2021
-
Patent Title: Kinase inhibitors and methods for making and using Jul. 13, 2021
-
Patent Title: Tgf-ß inhibitors Jun. 01, 2021
-
Patent Title: 2,4-pyrimidinediamine compounds and their uses May. 18, 2021
-
Patent Title: Rip1 inhibitory compounds and methods for making and using the same Apr. 13, 2021
-
Patent Title: Amide compounds and method for making and using Mar. 16, 2021
-
Patent Title: Irak inhibitors and method for making and using Mar. 09, 2021
-
Patent Title: Nrf2 activating compounds and uses thereof Mar. 09, 2021
-
Patent Title: Ampk-activating heterocyclic compounds and methods for using the same Mar. 09, 2021
-
Patent Title: Prodrugs of nrf2 activating compounds and uses thereof Jan. 12, 2021
-
Patent Title: 2,3-disubstituted pyridine compounds as tgf-β inhibitors and methods of use Dec. 08, 2020
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to RIGL
Recent picks made for RIGL stock on CNBC
ETFs with the largest estimated holdings in RIGL
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $RIGL stock a Buy, Sell, or Hold?
- What is the price target for $RIGL stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $RIGL stock?
- Who owns the most shares of $RIGL stock?
- What funds own $RIGL stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view RIGL Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.